

Preprints are preliminary reports that have not undergone peer review. They should not be considered conclusive, used to inform clinical practice, or referenced by the media as validated information.

# Nitrous Oxide activates layer 5 prefrontal neurons via SK2 channel inhibition for antidepressant effect

**Joseph Cichon** 

jmcichon@gmail.com

University of Pennsylvania https://orcid.org/0000-0003-4318-9707
Thomas Joseph
University of Pennsylvania https://orcid.org/0000-0003-1323-3244
Xinguo Lu
Washington University School of Medicine
Andrzej Wasilczuk
University of Pennsylvania https://orcid.org/0000-0002-1492-2319
Max Kelz
University of Pennsylvania
Steven Mennerick
Washington University in St. Louis
Charles Zorumski
University of Washington St Louis
Peter Nagele
University of Chicago

Article

Keywords:

Posted Date: November 15th, 2024

DOI: https://doi.org/10.21203/rs.3.rs-5141491/v1

License: (c) This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Additional Declarations: There is NO Competing Interest.

Nitrous Oxide activates layer 5 prefrontal neurons via SK2 channel inhibition for antidepressant effect

#### Author list:

Joseph Cichon<sup>1,2</sup>\*, Thomas T. Joseph<sup>1</sup>, Xinguo Lu<sup>3,4</sup>, Andrzej Z. Wasilczuk<sup>1</sup>, Max B. Kelz<sup>1,2</sup>, Steven J. Mennerick<sup>3,4</sup>, Charles F. Zorumski<sup>3,4</sup>, Peter Nagele<sup>5</sup>

#### **Affiliations:**

<sup>1</sup>Department of Anesthesiology and Critical Care, Perelman School of Medicine, University

of Pennsylvania, Philadelphia, PA, USA

<sup>2</sup>Mahoney Institute for Neurosciences, Perelman School of Medicine, University of

Pennsylvania, Philadelphia, PA, USA

<sup>3</sup>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO,

USA

<sup>4</sup>The Taylor Family Institute for Innovative Psychiatric Research, Washington University

**School of Medicine** 

<sup>5</sup>Department of Anesthesia and Critical Care, University of Chicago, Chicago, Illinois

\*Correspondence should be addressed to J.C. (joseph.cichon@pennmedicine.upenn.edu or jmcichon@gmail.com)

#### Abstract:

Nitrous oxide (N<sub>2</sub>O) induces rapid and durable antidepressant effects. The cellular and circuit mechanisms mediating this process are not known. Here we find that a single dose of inhaled N<sub>2</sub>O induces rapid and specific activation of layer V (L5) pyramidal neurons in the cingulate cortex of rodents exposed to chronic stress conditions. N<sub>2</sub>O-induced L5 activation rescues a stress-associated hypoactivity state, persists following exposure, and is necessary for its antidepressant-like activity. Although NMDA-receptor antagonism is believed to be a primary mechanism of action for N<sub>2</sub>O, L5 neurons activate even when NMDA-receptor function is attenuated through both pharmacological and genetic approaches. By examining different molecular and circuit targets, we identify N<sub>2</sub>O-induced inhibition of calcium-sensitive potassium (SK2) channels as a key molecular interaction responsible for driving specific L5 activity along with ensuing antidepressant-like effects. These results suggest that N<sub>2</sub>O-induced L5 activation is crucial for its fast antidepressant action and this effect involves novel and specific molecular actions in distinct cortical cell types.

#### Main text:

Major depression is a heterogenous condition that diminishes psychosocial functioning and quality of life. Despite advances in understanding pathophysiology and antidepressant mechanisms, up to one-third of patients have failed responses to conventional treatments (1, 2), possibly reflecting different subtypes affecting distinct cell types and neuronal networks (3). Prefrontal cortical (PFC) circuit dysfunction remains most consistently involved with depression severity tied to deficits in neuronal activity, plasticity, and structure (4–7). Both rodent models of chronic stress and depressed human patients show hypoactive PFC networks (4, 8, 9), impaired plasticity (10), and reduced synaptic number and brain volume (11–13). Existing treatments for depression reverse many disease-associated circuit defects but often have slow-onset (3, 14). Psychedelics and anesthetics, such as ketamine and nitrous oxide (N<sub>2</sub>O) (15–17), produce both rapid and sustained antidepressant effects following a single treatment in patients suffering from treatment-resistant depression (TRD). How these novel antidepressants enact their rapid and durable antidepressant effects is poorly understood.

The success of ketamine as a rapid antidepressant reawakened interest in N<sub>2</sub>O as a possible antidepressant (*18*, *19*). Two randomized controlled, early-phase clinical trials of N<sub>2</sub>O (25-50%) demonstrated promising results where TRD patients experienced rapid and sustained symptomatic relief, mirroring the rapid antidepressant effects of ketamine (*17*, *18*). Like ketamine, N<sub>2</sub>O's molecular mechanism on neuronal function is thought to involve NMDA-receptor (NMDA-R) antagonism (*20*, *21*), but this has never been directly tested *in vivo*. It remains unclear how N<sub>2</sub>O could drive rapid and durable therapeutic effects despite fast elimination from the brain (~5 min) and no metabolites (*22*). Here, we investigated the cellular and circuit basis for N<sub>2</sub>O's antidepressant effect by imaging PFC microcircuits before and after N<sub>2</sub>O treatment.

#### N<sub>2</sub>O's antidepressant-like response arises from rapid activation of L5 pyramidal neurons

Chronic stress is one important risk factor for depression (23). In animal models, chronic stress recapitulates key features of the depressed brain, including maladaptive changes in neuronal structure, function, and behaviors (24). In this work, we chronically stressed mice with two different strategies, 1) chronic corticosterone (referred to as CORT) in drinking water (25, 26) and 2) chronic exposure of a male C57BL/6 mouse to a male CD-1 aggressor mouse (termed chronic aggressor interactions or CAI)(Fig. 1A, fig. S1A-C, Supplemental Movie 1) (27, 28). Following chronic stress, animals displayed an anxiodepressive-like state as evidenced by prolonged immobility time in tail suspension test (TST)), decreased preference for sucrose in sucrose preference test, and reduced activity in open arms in the elevated plus maze as compared to controls exposed to daily handling (Fig. 1B-D). To determine if N<sub>2</sub>O exhibits rapid antidepressantlike effects in rodents exposed to chronic stress, we administered inhaled N<sub>2</sub>O (50%) or  $O_2$ (control; 100%) for 1 hr to head-restrained mice via a nose cone (Fig. 1A, fig. S1D). We chose a 50% N<sub>2</sub>O dose instead of 25% because of the open-circuit delivery method in rodent studies, unlike the semi-closed-circuit approach commonly used in human trials. We found that N<sub>2</sub>O drove the rapid (within 1 hr from treatment) reversal of chronic stress associated behaviors in both CORT and CAI mice compared to O<sub>2</sub>-treated controls (Fig. 1B-D). In a separate cohort of mice tracked only in TST we observed a sustained decrease in immobility time at 24 hr post treatment in both CORT and CAI mice but not in controls (fig. S1F). Although it is difficult to assess drug-induced behavioral effects in head-restrained mice, unrestrained mice in a closed chamber exposed to 50% N<sub>2</sub>O showed increased movement and exploration rather than signs of sedation (fig. S2).

Dysfunction of the medial PFC is a hallmark feature of human depression (6) and preclinical models of chronic stress (29, 30). To determine if chronic stress produces a similar

effect in rodent brain, we recorded the spontaneous activity of excitatory neurons across the cortical column in the cingulate cortex (Cg1), which is a supplemental motor area in rodents, by using two-photon (2-P) calcium imaging (**Fig. 1A**, right). Adeno-associated virus (AAV) encoding the calcium indicator GCaMP6f under the Calcium/Calmodulin dependent protein kinase II (CaMK2) promoter drove stable sensor expression specific to pyramidal neurons of superficial, *i.e.* layer (L) 2/3, and deep, L5, layers in this location (**fig. S3C**). Deep neurons of chronically stressed mice (CORT and CAI) showed a hypoactivity state in L5 as compared to controls (**Fig. 1E, G**), a finding consistent with this region reconfiguring to chronic stress (*8*). Thus, in agreement with previous reports (*29*), chronic stress in adult rodents induces both behavioral and neurophysiological changes consistent with a depression-like state.

Considering that N<sub>2</sub>O is believed to reduce both pre- and postsynaptic neuronal activity as a sedative-hypnotic with neuroprotective properties (20, 31), it was unclear how N<sub>2</sub>O would produce its rapid antidepressant effect in a stress-induced hypoactive cortical network. Here, inhaled N<sub>2</sub>O (50%) induced rapid activation of deep pyramidal neurons (Avg. cell location  $\pm$  std. error of mean, control: 573  $\pm$  17 µm, CORT: 623  $\pm$  14 µm, CAI: 619  $\pm$  16 µm) in both chronically stressed and control mice as compared to both superficially located L2/3 neurons (control: 315  $\pm$ 20 µm, CORT: 297  $\pm$  22 µm, CAI: 272  $\pm$  24 µm) and O<sub>2</sub> controls from the same region (**Fig. 1E-G**, **fig. S4A**, **D**, **Supplemental Movie 2**). Comparisons were made after 15 min of N<sub>2</sub>O exposure to ensure steady state gas concentration. Considering Cg1's anatomical location and cytoarchitecture, we proposed the deep pyramidal neurons recruited by N<sub>2</sub>O are likely within L5. L5 identity was further supported by calcium imaging in specific L5 transgenic Cre lines, where N<sub>2</sub>O recruited Rbp4 and Tlx3 expressing cells, but not Colgalt2 (**Fig. 1H**) (*32*). Furthermore, calcium imaging of CaMK2-expressing cells at a depth of >500-600 µm from the pial surface in secondary motor cortex (**fig. S4B**) and primary somatosensory cortex (**fig. S4B-C**) also revealed putative L5 neuronal activation as compared to L2/3. Therefore, we refer to this N<sub>2</sub>O-recruited deep neuronal population as L5 hereon.

Within a local imaging field of view, N<sub>2</sub>O-active L5 cells generated large asynchronous calcium transients, resembling a form of burst-like firing (**fig. S4E-G**) (*33*). Given the sustained nature of these transients, we show calcium activity as area under the curve (AUC) of the  $\Delta$ F/F<sub>0</sub> trace for an individual neuron, reflecting changes in both frequency and amplitude (**fig. S4H**). A dose-response curve of CaMK2-expressing L5 population in Cg1 revealed a peak activation effect at 50% as opposed to 25 or 75% N<sub>2</sub>O (**Fig. 11, fig. S1E**). Electroencephalogram (EEG) recordings over the same N<sub>2</sub>O concentration steps revealed higher frequency oscillations at 50% as compared to 25 or 75% (**fig. S5**). These results suggest that at doses found to have antidepressant effects in human patients suffering from TRD (*17, 18*), N<sub>2</sub>O inhalation drives a rapid activation of the same class of neurons most profoundly affected by chronic stress in rodents (**Fig. 1G**) (*29*).

Because N<sub>2</sub>O activates L5 from its baseline hypoactive state in chronically stressed mice, we wondered if this activation plays a pivotal role in N<sub>2</sub>O's antidepressant response. To specifically increase L5 activity *in vivo* (in absence of N<sub>2</sub>O), we specifically transfected Rbp4 Creexpressing mice with an AAV encoding Cre-dependent hM<sub>3</sub>D(G<sub>q</sub>) designer receptor exclusively activated by designer drug (DREADD) receptor in Cg1 bilaterally (**Fig. 1J, fig. S6A**). The binding of the ligand clozapine *N*-oxide (CNO) to hM<sub>3</sub>D(G<sub>q</sub>) receptors activates G<sub>q</sub>-coupled signaling, leading to membrane depolarization and increased firing of target cells through multiple mechanisms (*34*). CNO delivered by i.p. injection to mice expressing hM<sub>3</sub>D(G<sub>q</sub>) specifically in L5 cells induced a ~2-3-fold increase in spontaneous calcium activity (when assessed at 1 and 3 hrs later) and a rapid antidepressant-like effect detected within 1 hr that lasted at least for 1 day (**Fig.**  **1J, fig. S6B-D**). This behavioral effect induced by  $hM_3D(G_q)$  in L5 masked N<sub>2</sub>O's effect when CNO was delivered prior to N<sub>2</sub>O (**Fig. 1K**). Conversely, L5 inactivation by DREADD- $hM_4D(G_i)$ acutely blocked N<sub>2</sub>O's ability to recruit L5 and its accompanying antidepressant effect when CNO was delivered prior to N<sub>2</sub>O (**Fig. 1J-K, fig. S6B**). These results suggest that a single N<sub>2</sub>O treatment induces rapid and specific activation of L5 neurons in Cg1 to rescue chronic stress-associated hypoactivity and that recruitment of these cells is required for N<sub>2</sub>O's ensuing antidepressant-like effect.

#### N<sub>2</sub>O-induced rescue of stress associated L5 hypoactivity persists following drug elimination

N<sub>2</sub>O is rapidly cleared from the brain/body within minutes (via expiration) without active metabolites (*35*). To determine if N<sub>2</sub>O's acute L5 activation contributes to its lasting antidepressant-like effect, we followed the same L5 populations following N<sub>2</sub>O exhalation. To our surprise, we found persistent L5 activity in both chronically stressed and control mice 1 hr following N<sub>2</sub>O exposure but not in O<sub>2</sub> treated mice (**Fig. 2A, C, fig. S7A**). L5 responses persisted for at least 3 hrs in chronically stressed mice whereas control mice showed a normalization to baseline activity patterns recorded under room air (**fig. S7B**). In some cases where L5 was tracked over 24 hours, we found evidence of persistent activity (**fig. S7D**). At these follow-up time points, superficial L2/3 cells, previously weakly active or not active, were now found to be spontaneously active (**Fig. 2B-C**). Newly active L2/3 activity also persisted for hours (**Fig. 2B-C, fig. S7D**).

Given that L5 was recruited during N<sub>2</sub>O exposure and both L5 and L2/3 have persistent spontaneous activity post-treatment, we suspected that N<sub>2</sub>O-L5 activation contributes to the recruitment and sustained activation of local L2/3 neurons in Cg1 (**Fig. 2D**). To determine if local L5 neuronal activity can drive local L2/3 activation, L5-specific Rbp4-Cre mice were transfected

with AAVs encoding Cre-dependent  $hM_3D(G_q)$  and synapsin-GCaMP6f for DREADD-induced L5 activation while recording L2/3 calcium responses respectively (Fig. 2E, left schematic). CNOinduced L5 activation drove L2/3 activation (2.5-fold increase in spontaneous activity) 20-30 min following CNO injection (Fig. 2F-G). To ascertain if post-N<sub>2</sub>O exposure L5 activity drives local L2/3 activity in chronically stressed mice, CORT-treated Rbp4 mice expressing hM<sub>4</sub>D(G<sub>i</sub>) (unilateral expression) were exposed to N<sub>2</sub>O to drive L5 activation and persistent activity. L5 neurons were then chemogenetically inactivated by hM<sub>4</sub>G<sub>i</sub>, meanwhile recording ipsilateral L2/3 neuronal activity (Fig. 2E, right schematic). Following CNO injection (imaging 20-30 min after CNO), post N<sub>2</sub>O-induced L2/3 activity was significantly reduced by L5 inactivation (Fig. 2F-G). We suspected the residual L2/3 activity (~50% increase over baseline) following local L5 silencing could be explained by long-range L5 projections (both ipsilateral and contralateral) into Cg1 (Fig. **2E**). In agreement with this hypothesis, bilateral inhibition of Cg1 L5 neurons post- $N_2O$  further reduced spontaneous L2/3 activity (~18% decrease from baseline) (Fig. 2F-G). Furthermore, bilateral inhibition of both L2/3 and L5 activity post-N<sub>2</sub>O via CNO-induced hM<sub>4</sub>G<sub>i</sub> signaling promoted the reversal N<sub>2</sub>O-induced antidepressant effect (fig. S7C). These experiments demonstrate that N<sub>2</sub>O exposure drives the rapid and persistent activity of L5 neurons. Following N<sub>2</sub>O elimination, L5 neurons contribute to the recruitment of excitatory neurons in interconnected circuits, which contributes N<sub>2</sub>O's antidepressant-like response.

#### Reduced NMDA-R function does not block N<sub>2</sub>O-induced L5 activation

 $N_2O$ -induced L5 rapid and persistent activity is seemingly at odds with  $N_2O$ 's known molecular mechanism as an NMDA-R antagonist as NMDA-R block would likely attenuate neuronal activity (36–38). To determine if NMDA-R activity is required for  $N_2O$ -induced L5 rapid

and persistent activity, we recorded L5 responses before and after local application NMDA-R antagonists (both D-APV and MK801) delivered to Cg1 through a small bone hole lateral to the imaging region (*39*, *40*), and once again in the presence of N<sub>2</sub>O (**Fig. 3A**). Consistent with the expected effects of potent NMDA-R antagonists, both D-APV and MK801 ( $100 \mu$ M, 1  $\mu$ L) suppressed spontaneous L5 calcium activity. N<sub>2</sub>O, however, retained its ability to recruit L5 activity even in the presence of NMDA-R blockers (**Fig. 3B**, **D**, **fig. S8A**). Lower concentrations of MK801 ( $10 \mu$ M, 1  $\mu$ L) yielded a similar N<sub>2</sub>O-induced effect despite increasing baseline L5 activity (**Fig. 3B, D**). Furthermore, L5 activity even persisted following local co-application of potent excitatory synaptic blockers - MK801 and AMPA receptor blocker CNQX (each 100  $\mu$ M, total volume 1  $\mu$ L; **Fig. 3B, D**). Thus, in the presence of either NMDA-R blockers or excitatory synaptic blockers, N<sub>2</sub>O retains its ability to rapidly activate L5.

When L5 neurons were followed post-N<sub>2</sub>O exposure, NMDA-R blockers significantly reduced N<sub>2</sub>O's effect on persistent L5 activity (**fig. S8A**). Similarly, in mice first treated with N<sub>2</sub>O and then exposed to local NMDA-R blocker, N<sub>2</sub>O-induced L5 persistent activity was significantly dampened (**fig. S8A-B**). Therefore, L5 activation and persistent activity could be manifested by two distinct mechanisms: 1) an unknown, NMDA-R-independent activation mechanism, 2) persistent activity maintained by NMDA-R-dependent activity. In support of this claim, N<sub>2</sub>O inhalation drove L5 activation in the presence of NMDA-R subunit 1 (NR1) expression knockdown via siRNA targeted to GRIN1, but with a significant impairment in persistent activity during or post N<sub>2</sub>O exposure (**Fig. 3C-D**). Thus, contrary to its proposed mechanism of action through NMDA-R antagonism, our findings show that N<sub>2</sub>O rapidly activates L5 neurons even when NMDA-R function is diminished.

Similar to N<sub>2</sub>O, ketamine is believed to exert its rapid and long-lasting antidepressant effects primarily through NMDA receptor antagonism (*15*, *16*). Given that N<sub>2</sub>O-induced activation of L5 neurons occurs even with reduced NMDA receptor function, we hypothesized that ketamine and N<sub>2</sub>O would modulate the spontaneous activity of local Cg1 L5 neurons in distinct ways. To this end, we followed L5 populations through different iterations of N<sub>2</sub>O and subhypnotic ketamine exposures and found L5 neurons displayed opposing modulation by the two drugs (**Fig 3E-G**). While N<sub>2</sub>O drove the stronger L5 response between the two treatments, ketamine-activated L5 neurons showed little overlap with N<sub>2</sub>O-activated cohort (**Fig 3G**). Local application of ketamine (100  $\mu$ M, 1  $\mu$ L) failed to block or recapitulate N<sub>2</sub>O-induced L5 activation (**Fig. 3E-F**). When systemic ketamine was delivered before or in between two N<sub>2</sub>O exposures, ketamine inhibited the succeeding N<sub>2</sub>O-induced L5 activation (**Fig 3E-F**). Therefore, N<sub>2</sub>O and ketamine have highly divergent modulations of L5 activity. This implies both drugs likely engage different cellular and circuit mechanisms to achieve their acute antidepressant effects.

N<sub>2</sub>O-induced L5 recruitment in the presence of synaptic blockers suggests a synapticindependent mechanism. To specifically address this hypothesis, we performed dendritic imaging across individually labelled L5 neurons (different cohort from mice in Fig. 1-3). Using a sparse AAV labelling approach, individual L5 neurons expressing both GCaMP6 and tdTomato (structural marker) can be mapped within an imaging window from apical dendritic tree down to L5 soma (**Fig. 4B**). In dendritic segments confined to layer 1 ( $63 \pm 8.3 \mu m$ ), N<sub>2</sub>O did not significantly increase the spontaneous activity of postsynaptic dendritic spines nor the generation of dendritic branch calcium events (**Fig. 4A-C, fig. S9A**). Deeper imaging of dendritic branch points (tuft:  $100 \pm 7.6 \mu m$ ) also revealed no significant elevation in spontaneous calcium events comparable to baseline (**Fig 4B-C**). L2/3 neurons were occasionally labelled with this technique  $(316 \pm 21 \ \mu\text{m})$  were not recruited by N<sub>2</sub>O (**fig. S9B**). Imaging at the location of L5 soma (627 ± 15  $\mu$ m) and trunks (333 ± 31  $\mu$ m) demonstrated robust N<sub>2</sub>O-induced activation (**Fig. 4B-C, fig. S9A**).

While high-resolution imaging of dendritic segments captures a small portion of the L5 neuron's apical tuft at a given time (**Fig. 4A-B**), it is conceivable that other dendritic branches are active and contributing top-down inputs that were missed. To address this possibility, we performed two-photon laser directed apical tuft dendritic cuts (*41*), or dendritomies, from L5 cells during N<sub>2</sub>O administration and recorded the impact on L5 responses. N<sub>2</sub>O still drove L5 activation despite apical dendrites being physically separated from their soma (**Fig. 4D-E**, **fig. S9C**). Furthermore, in an *in vitro* low-density primary cortical neuronal culture (free of network variables), where synaptic connectivity is reduced (no detectable spontaneous calcium activity prior to N<sub>2</sub>O), N<sub>2</sub>O-bubbled bath solution induced the rapid activation of a subset of putative pyramidal cortical neurons (**fig. S10**). Therefore, N<sub>2</sub>O-induced L5 activation arises independently of NMDA-R activity and synaptic inputs and likely engages a novel, unknown somatic activation mechanism. Nevertheless, the persistent L5 activity observed following N<sub>2</sub>O exposure requires NMDA-R activity.

## N<sub>2</sub>O-induced disinhibition of GABAergic interneurons promotes L5 activity and antidepressant-like effects

The absence of enhanced synaptic inputs or organized dendritic activity suggests  $N_2O$  is driving rapid changes in L5 excitability through a novel somatic mechanism: either a molecular interaction, circuit reconfiguration, or a combination of the two. To this end, we evaluated several candidate channels and receptors that could hypothetically contribute to changes in L5 excitability by imaging L5 responses before and after local delivery of specific channel blockers followed by N<sub>2</sub>O. Functional attenuation of voltage-gated sodium channels, voltage-gated calcium channels, serotonin reuptake transporters, mu opioid receptors, and channels controlling the intracellular release of calcium stores (both IP<sub>3</sub> and ryanodine) failed to block N<sub>2</sub>O's rapid L5 activation (**fig. S11A-B**). Despite N<sub>2</sub>O-induced L5 recruitment under these conditions, we did observe predicted changes in L5 calcium signal strength and duration imposed by the local drug indicating adequate diffusion to L5 (**fig. S11A-B**).

Next, we evaluated whether GABA receptor neuromodulation could regulate N<sub>2</sub>O-induced activity. By taking advantage of the GABAergic volatile anesthetic gas isoflurane, which is often coadministrated with N<sub>2</sub>O in clinical practice, we found that subhypnotic isoflurane concentrations, both 0.2% and 0.6%, mixed with N<sub>2</sub>O (50%) blocked the rapid recruitment of L5 neurons (**fig. S12A, C**). Similarly, local application of a potent and selective GABA<sub>A</sub>-R agonist muscimol induced a strong blockade of N<sub>2</sub>O-evoked L5 activity (**fig. S12B-C**). The coadministration of isoflurane (0.6%) with N<sub>2</sub>O (50%) also eliminated N<sub>2</sub>O's antidepressant-like effect (**fig. S12D**). Thus, N<sub>2</sub>O-induced L5 recruitment is highly sensitive to acute changes in GABA receptor-mediated inhibition and supports the conjecture that N<sub>2</sub>O-induced L5 activity is necessary for its antidepressant-like effects.

While  $N_2O$  appears to interact weakly with postsynaptic GABAergic receptors (42), the action of  $N_2O$  on GABA-releasing interneurons is unknown. GABAergic interneurons target specific domains of pyramidal neurons and other local interneurons, providing precise control of excitatory and inhibitory outputs and cortical dynamics (**Fig. 5A**). A rapid shift in cortical inhibition could present one mechanism to explain  $N_2O$ 's effect on pyramidal cell excitability. To determine if interneurons contribute to  $N_2O$ -induced L5 activity, first we mapped spontaneous

activity of interneuron responses under room air and during N<sub>2</sub>O exposure in mice expressing GCaMP6 under the m*Dlx* enhancer, a specific labelling strategy for GABAergic interneurons (**Fig. 5B-C**) (*43*). We found that N<sub>2</sub>O induced the overall suppression of interneurons activities from baseline wakefulness (110/137 cells) with only a small subset of cells becoming recruited by N<sub>2</sub>O (**Fig. 5C, fig. S13A**). Three genetically defined subtypes: PV-, SST-, VIP-expressing interneurons are subsumed within the m*Dlx*-defined interneuron population (**Fig. 5A**, right cartoon). We suspected that the small population of m*Dlx cells* recruited by N<sub>2</sub>O was specific to one of these subtypes. By taking advantage of several interneuron-specific Cre driver lines coupled with AAV transfection of Cre-dependent GCaMP6f, we examined the activity profiles of interneurons in Cg1 (**Fig. 5B**). Here, we found that N<sub>2</sub>O-induced the downregulation of PV and SST activities from baseline measurements (**Fig. 5C, fig. S12A**). In contrast to PV and SST activities, N<sub>2</sub>O increased VIP activity (**Fig. 5C, fig. S12A**). Therefore, N<sub>2</sub>O induces the rapid reconfiguration of local interneurons favoring the establishment of a disinhibitory circuit, a motif akin to ketamine (*39*).

To assess whether the N<sub>2</sub>O-induced downregulation of PV or SST activities is required for L5 activation, we attempted to counteract the suppression of interneuron activity induced by N<sub>2</sub>O by autonomously activating these cells using DREADD variant  $hM_3D(G_q)$  (**fig. S13B**). To drive interneuron activity *in vivo*, CNO-injected mice coexpressing GcaMP6f and  $hM_3D(G_q)$  specifically in PV, SST, and VIP-expressing cells induced more than two-fold increase in spontaneous calcium activity in wakefulness (**Fig. 5D**). CNO-mediated interneuron activation was maintained in the presence of N<sub>2</sub>O (**Fig. 5D**). Next, we activated these interneuronal subtypes individually before N<sub>2</sub>O while monitoring L5 neuronal activity. CNO-induced activation of either PV or SST interneurons prevented the N<sub>2</sub>O-induced L5 activity (**Fig. 5E**). Similarly, if CNO was given after N<sub>2</sub>O (instead of before), N<sub>2</sub>O-induced L5 activation was quickly abolished (**fig. S13D**).

By contrast, CNO-induced VIP activation did not prevent the N<sub>2</sub>O-induced L5 activity (**Fig. 5E**). In control mice expressing tdTomato, CNO did not impair N<sub>2</sub>O's L5 response (**fig. S13C**). Furthermore, the presence of N<sub>2</sub>O-induced L5 activation (VIP activation) led to an antidepressantlike response where its absence (PV or SST activation) did not (**Fig. 5F**). Taken together these experiments suggest N<sub>2</sub>O induces a disinhibitory circuit favoring an increase in L5 activity.

Such a dramatic shift in SST and PV-expressing populations should indiscriminately favor pyramidal cell activation (excitatory cells in L2/3 and L5) given known patterns of connectivity. While N<sub>2</sub>O-induced disinhibition enables L5 activity it fails to account for N<sub>2</sub>O's observed L5 specificity. Therefore, we reasoned that an unidentified specific molecular interaction in both VIP and L5 neurons could explain N<sub>2</sub>O's cellular and circuit changes in cortex.

#### SK2 channel inhibition reproduces L5 and VIP cell activation and antidepressant-like effects

N<sub>2</sub>O's well described *in vitro* NMDA-R antagonism effects are unlikely to underlie the activation of both L5 and VIP cells *in vivo* (**Fig. 3**). We predicted N<sub>2</sub>O's ability to recruit L5 and VIP cells would rest upon a shared mechanism in both cell types, given the lack of direct connectivity between the two cell types (44), which would regulate acute changes in excitability and depolarization to drive rapid and persistent L5 activity. To this end, we explored single-cell RNA expression levels of receptors and ion channels across genetically defined pyramidal and interneuron cell types using the open source Allen Brain Cell Atlas (**fig. S14A**) (45). We uncovered a voltage-insensitive, calcium-sensitive potassium channel 2 (SK2 channel encoded by gene KCNN2) as a potential molecular target given: 1) its increased RNA expression in both L5 and VIP cells (**fig. S14A**), 2) SK2 protein immunohistochemistry and KCNN2 in situ hybridization identifying predominant L5 expression (**Fig. 6A, fig. S14B**) (46), 3) its role in regulating pyramidal

cell intrinsic excitability and plasticity (47, 48), 4) SK channel inhibition induces antidepressant effects in rodents (49, 50).

First, we investigated the effects of N<sub>2</sub>O on the medium afterhyperpolarization (mAHP), the major function of SK2 channels, in Cg1 L5 neurons in acute brain slices (*51*, *52*). mAHPs were elicited by step-current injections ranging from 200 to 400 pA. Here, bubbled N<sub>2</sub>O bath (30%) induced significant reduction in mAHP amplitude across all tested current injection intensities as compared to baseline measurements (**Fig. 6B-C**). To ensure that the observed effects were specific to N<sub>2</sub>O and not the result of non-specific actions of gas application, we conducted control experiments using 30% nitrogen (N<sub>2</sub>). As shown in **Fig. 6D-E**, N<sub>2</sub> application did not alter mAHP amplitudes across any of the tested current intensities. These results demonstrate that N<sub>2</sub>O robustly reduces mAHP in cortical L5 pyramidal neurons.

Next, using the approach detailed in **Fig. 3**, we explored whether local pharmacologic inhibition of SK2 channel function with specific inhibitor, apamin, could drive the spontaneous activation of neurons expressing SK2. Here, L5 and VIP neurons, but not L2/3 pyramidal cells or interneurons (PV or SST), were spontaneous recruited by apamin (**Fig. 7A-B**). NS 8593, a selective SK2 negative modulator, drove similar L5 responses (**Fig. 7B**). The spontaneous recruitment of L5 even occurred in the presence of local NMDA-R blockade with D-APV, confirming the NMDA-R-independent nature of this process (**Fig. 7B**). In contrast, local application of CyPPA, a SK2 channel activator, prior to N<sub>2</sub>O exposure reduced N<sub>2</sub>O-induced L5 activity (**fig. S15A**). Like N<sub>2</sub>O, a single apamin i.p. injection induced rapid antidepressant-like response in stressed mice (**Fig. 7C**).

Consistent with these pharmacologic manipulations, SK2 channel overexpression in L2/3 cell types, which normally do not express SK2 (*i.e.* pyramidal cells, PV, SST), enable acute N<sub>2</sub>O

activation (**Fig. 7D-E, fig. S15B**). Knockdown of endogenous SK2 expression in L5 using Rbp4-Cre and Cre-dependent AAV encoding shRNA for KCNN2 prevented N<sub>2</sub>O-induced L5 activation and its ensuing rapid antidepressant-like response (**Fig. 7D-F, fig. S15C-D**). Collectively, these experiments suggest SK2 channel inhibition is necessary and sufficient to reproduce N<sub>2</sub>O's effect on both L5 and VIP cell function and drive its antidepressant-like response.

#### N<sub>2</sub>O-induced SK2 channel inhibition via channel pore blockade

We hypothesized that N<sub>2</sub>O might inhibit channel function by interacting with its selectivity filter, anticipating that the doses of N2O required for clinical effect would allow enough N2O molecules to bind in the filter and yield a response, even if a large energetic barrier must be traversed. To evaluate this idea, we performed all-atom molecular dynamics (MD) simulation of an SK2 homology model with a single N<sub>2</sub>O molecule placed manually in its selectivity filter. In equilibrium MD simulation, the N<sub>2</sub>O molecule remained trapped in the selectivity filter with no migration (Fig. 8A-C). To quantify the energetic barriers to N<sub>2</sub>O escape, we calculated a potential of mean force (PMF) profile of free energy of N<sub>2</sub>O diffusion along the pore axis in the region of the selectivity filter using the adaptive biasing force (ABF) method (53) which would allow recovery of a free energy profile across large energy barriers. The PMF profiles from replicate ABF simulations revealed that displacing the bound N<sub>2</sub>O 2 Å or more to approach either opening of the filter requires traversing an energy barrier of at least 8 kcal/mol (fig. S16). Because the SK2 structure was a homology model, we chose not to exhaustively evaluate the numerous diffusion pathways available to N<sub>2</sub>O moving intracellularly away from the selectivity filter (regions with larger errors in fig. S16) and therefore we draw no conclusions from these regions of the PMF. Overall, these data support the hypothesis that N<sub>2</sub>O may attenuate SK2 channel function in the

activated state by becoming trapped in its selectivity filter (47). Moreover, SK2 with stably trapped  $N_2O$  likely contributes to the experimentally observed persistent L5 activity following  $N_2O$  discontinuation.

#### Discussion

While N<sub>2</sub>O has shown therapeutic promise for severe TRD, its molecular and circuit mechanisms of action are unknown. Using *in vivo* calcium imaging across Cg1 cortical layers and cell types in mice exposed to chronic stress, we show that subhypnotic N<sub>2</sub>O induces rapid and specific activation of L5 neurons that persists long after N<sub>2</sub>O clearance from the animal. L5 activation was crucial for rescuing stress-induced circuit hypoactivity in both L5 and L2/3 and driving a rapid antidepressant-like responses. Because synaptic loss and impaired connectivity are key features of chronic stress and depressive states in rodents and humans (4, 8-10), these results provide a tangible mechanism for how a single drug treatment can re-awaken existing dysfunctional circuits without the formation of new synaptic connections and contribute to rapid changes in behaviors (**Fig. 8D**). The formation of synapses in response to N<sub>2</sub>O could contribute to stability of L5 and/or L2/3 activity and maintain these improvements over days. The extent and timescale over which N<sub>2</sub>O-induced activity modulates new synapse formation requires future studies.

Our studies indicate that N<sub>2</sub>O has important mechanisms of action in cortical circuits beyond those observed in hippocampus and other brain regions. In particular, NMDA-R inhibition does not contribute to N<sub>2</sub>O-induced cortical L5 activity patterns as evidenced by 1) N<sub>2</sub>O-induces L5 activity in presence of NMDA-R blockers or GRIN1/NR1 knockdown (**Fig. 3**), 2) ketamine and N<sub>2</sub>O differentially modulate the same population of L5 cells when the drugs given in succession (**Fig. 3**), 3) subcellular imaging at the level of synapses and dendritic branches reveals no upregulation of synaptic inputs or dendritic calcium spikes (**Fig. 4**), and 4) dendritomies of apical dendritic branches from individual cells failed to abolish N<sub>2</sub>O-induced L5 activity (**Fig. 4**). Although N<sub>2</sub>O can recruit L5 neurons even under conditions of low NMDA receptor activity, the sustained L5 activity and neuroplasticity following N<sub>2</sub>O elimination likely requires NMDA receptor signaling (**fig. S8**)(*54*). This is in line with recent findings suggesting that ketamine may also depend on NMDA receptor signaling to produce its antidepressant-like behavioral effects (*55*).

In further search of an activating mechanism, we evaluated a series of molecular targets central to L5 excitability (**fig. S11-12**). Enhanced GABAergic tone via inhalation of subhypnotic concentrations of isoflurane or local application of muscimol eliminated N<sub>2</sub>O-induced L5 activity (**Fig. 12**). Calcium imaging of distinct GABAergic interneuron types revealed that N<sub>2</sub>O engages a specific disinhibition circuit via VIP-expressing cell recruitment with downregulation of PV- and SST-expressing neuronal activities (**Fig. 5, 8D**). This shift in the inhibitory interneuron network favoring pyramidal cell excitation was necessary for N<sub>2</sub>O-induced effect on L5 activity and behavior (**Fig. 5**). Thus, acute modulation of GABAergic interneurons by N<sub>2</sub>O, like subhypnotic ketamine, yielding a disinhibited cortical circuit might represent a unifying circuit phenotype to explain how these anesthetics enact their rapid-acting antidepressant action (*39, 56, 57*). Dysfunctional stress-sensitive circuits could require transient drug-induced changes in inhibition to allow selective patterns of excitatory activity to propagate through cortex and engage rapid and durable forms of activity-dependent synaptic plasticity (**Fig. 8D**) (*58*).

Despite emergence of a disinhibited network, we reasoned that  $N_2O$ -induced cell specificity must arise via an unknown molecular target, unique to L5 neurons and VIP interneurons. We identified SK2 channels as an attractive candidate with predominant L5

expression and sparse expression in L2/3. N<sub>2</sub>O, but not N<sub>2</sub> gas, inhibited SK2-mediated mAHPs *in vitro* (**Fig. 6**). Local pharmacological inhibition of SK2 in Cg1 drove spontaneous activity in L5 and VIP, but not other cell types, and a N<sub>2</sub>O-like antidepressant response (**Fig. 7**). SK2 overexpression and knockdown experiments in various cell-types support the effect of N<sub>2</sub>O acting as a SK2 channel inhibitor. Furthermore, MD simulations advanced our biophysical theory of N<sub>2</sub>O acting as a blocker in the highly conserved SK2 channel selectivity filter, where N<sub>2</sub>O traverses a substantial energy barrier to enter or exit its selectivity filter and inhibit channel function – potassium ion efflux and hyperpolarization (**Fig. 8**). Altogether, these findings indicate that N<sub>2</sub>O-induced rapid and sustained restructuring of prefrontal L5 neuronal activity is crucial for its antidepressant action and that this effect involves novel and specific molecular actions in distinct cortical cell types.

#### References

- 1. D. Warden, A. J. Rush, M. H. Trivedi, M. Fava, S. R. Wisniewski, The STAR\*D Project results: a comprehensive review of findings. *Curr. Psychiatry Rep.* 9, 449–459 (2007).
- 2. B. N. Gaynes, D. Warden, M. H. Trivedi, S. R. Wisniewski, M. Fava, A. J. Rush, What did STAR\*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. *Psychiatr. Serv.* **60**, 1439–1445 (2009).
- 3. P. K. Parekh, S. B. Johnson, C. Liston, Synaptic Mechanisms Regulating Mood State Transitions in Depression. *Annu. Rev. Neurosci.* **45**, 581–601 (2022).
- 4. W. C. Drevets, J. L. Price, J. R. Simpson Jr, R. D. Todd, T. Reich, M. Vannier, M. E. Raichle, Subgenual prefrontal cortex abnormalities in mood disorders. *Nature* **386**, 824–827 (1997).
- 5. H. K. Manji, W. C. Drevets, D. S. Charney, The cellular neurobiology of depression. *Nat. Med.* 7, 541–547 (2001).
- 6. M. S. George, T. A. Ketter, R. M. Post, Prefrontal cortex dysfunction in clinical depression. *Depression* **2**, 59–72 (1994).
- 7. D. A. Pizzagalli, A. C. Roberts, Prefrontal cortex and depression. *Neuropsychopharmacology* **47**, 225–246 (2022).
- C. L. Fales, D. M. Barch, M. M. Rundle, M. A. Mintun, J. Mathews, A. Z. Snyder, Y. I. Sheline, Antidepressant treatment normalizes hypoactivity in dorsolateral prefrontal cortex during emotional interference processing in major depression. *J. Affect. Disord.* **112**, 206– 211 (2009).
- H. E. Covington 3rd, M. K. Lobo, I. Maze, V. Vialou, J. M. Hyman, S. Zaman, Q. LaPlant, E. Mouzon, S. Ghose, C. A. Tamminga, R. L. Neve, K. Deisseroth, E. J. Nestler, Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. *J. Neurosci.* 30, 16082–16090 (2010).
- D. S. Goldwater, C. Pavlides, R. G. Hunter, E. B. Bloss, P. R. Hof, B. S. McEwen, J. H. Morrison, Structural and functional alterations to rat medial prefrontal cortex following chronic restraint stress and recovery. *Neuroscience* 164, 798–808 (2009).
- 11. G. Rajkowska, J. J. Miguel-Hidalgo, J. Wei, G. Dilley, S. D. Pittman, H. Y. Meltzer, J. C. Overholser, B. L. Roth, C. A. Stockmeier, Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. *Biol. Psychiatry* **45**, 1085–1098 (1999).
- H. J. Kang, B. Voleti, T. Hajszan, G. Rajkowska, C. A. Stockmeier, P. Licznerski, A. Lepack, M. S. Majik, L. S. Jeong, M. Banasr, H. Son, R. S. Duman, Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. *Nat. Med.* 18, 1413–1417 (2012).
- 13. D. J. Christoffel, S. A. Golden, S. J. Russo, Structural and synaptic plasticity in stress-

related disorders. Rev. Neurosci. 22, 535-549 (2011).

- R. S. Duman, G. K. Aghajanian, G. Sanacora, J. H. Krystal, Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. *Nat. Med.* 22, 238– 249 (2016).
- C. A. Zarate Jr, J. B. Singh, P. J. Carlson, N. E. Brutsche, R. Ameli, D. A. Luckenbaugh, D. S. Charney, H. K. Manji, A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Arch. Gen. Psychiatry* 63, 856–864 (2006).
- R. M. Berman, A. Cappiello, A. Anand, D. A. Oren, G. R. Heninger, D. S. Charney, J. H. Krystal, Antidepressant effects of ketamine in depressed patients. [Preprint] (2000). https://doi.org/10.1016/s0006-3223(99)00230-9.
- P. Nagele, B. J. Palanca, B. Gott, F. Brown, L. Barnes, T. Nguyen, W. Xiong, N. C. Salloum, G. D. Espejo, C. N. Lessov-Schlaggar, N. Jain, W. W. L. Cheng, H. Komen, B. Yee, J. D. Bolzenius, A. Janski, R. Gibbons, C. F. Zorumski, C. R. Conway, A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression. *Sci. Transl. Med.* 13, eabe1376 (2021).
- P. Nagele, A. Duma, M. Kopec, M. A. Gebara, A. Parsoei, M. Walker, A. Janski, V. N. Panagopoulos, P. Cristancho, J. P. Miller, C. F. Zorumski, C. R. Conway, Nitrous oxide for treatment-resistant major depression: A proof-of-concept trial. *Biol. Psychiatry* 78, 10–18 (2015).
- 19. M. A. Gillman, Mini-review: A brief history of nitrous oxide (N2O) use in neuropsychiatry. *Curr. Drug Res. Rev.* **11**, 12–20 (2019).
- V. Jevtović-Todorović, S. M. Todorović, S. Mennerick, S. Powell, K. Dikranian, N. Benshoff, C. F. Zorumski, J. W. Olney, Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. *Nat. Med.* 4, 460–463 (1998).
- 21. D. E. Emmanouil, R. M. Quock, Advances in understanding the actions of nitrous oxide. *Anesth. Prog.* 54, 9–18 (2007).
- 22. S. Einarsson, O. Stenqvist, A. Bengtsson, E. Houltz, J. P. Bengtson, Nitrous oxide elimination and diffusion hypoxia during normo- and hypoventilation. *Br. J. Anaesth.* **71**, 189–193 (1993).
- 23. S. J. Lupien, B. S. McEwen, M. R. Gunnar, C. Heim, Effects of stress throughout the lifespan on the brain, behaviour and cognition. *Nat. Rev. Neurosci.* **10**, 434–445 (2009).
- 24. E. J. Nestler, M. Barrot, R. J. DiLeone, A. J. Eisch, S. J. Gold, L. M. Monteggia, Neurobiology of depression. *Neuron* **34**, 13–25 (2002).
- 25. Y. Zhao, R. Ma, J. Shen, H. Su, D. Xing, L. Du, A mouse model of depression induced by repeated corticosterone injections. *Eur. J. Pharmacol.* **581**, 113–120 (2008).

- 26. S. L. Gourley, D. D. Kiraly, J. L. Howell, P. Olausson, J. R. Taylor, Acute hippocampal brain-derived neurotrophic factor restores motivational and forced swim performance after corticosterone. *Biol. Psychiatry* **64**, 884–890 (2008).
- 27. J. M. Koolhaas, S. F. De Boer, A. J. De Rutter, P. Meerlo, A. Sgoifo, Social stress in rats and mice. *Acta Physiol. Scand. Suppl.* **640**, 69–72 (1997).
- 28. N. N. Kudryavtseva, I. V. Bakshtanovskaya, L. A. Koryakina, Social model of depression in mice of C57BL/6J strain. *Pharmacol. Biochem. Behav.* **38**, 315–320 (1991).
- R. N. Moda-Sava, M. H. Murdock, P. K. Parekh, R. N. Fetcho, B. S. Huang, T. N. Huynh, J. Witztum, D. C. Shaver, D. L. Rosenthal, E. J. Alway, K. Lopez, Y. Meng, L. Nellissen, L. Grosenick, T. A. Milner, K. Deisseroth, H. Bito, H. Kasai, C. Liston, Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. *Science* 364 (2019).
- N. Li, R.-J. Liu, J. M. Dwyer, M. Banasr, B. Lee, H. Son, X.-Y. Li, G. Aghajanian, R. S. Duman, Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. *Biol. Psychiatry* 69, 754–761 (2011).
- 31. J. H. Abraini, H. N. David, M. Lemaire, Potentially neuroprotective and therapeutic properties of nitrous oxide and xenon. *Ann. N. Y. Acad. Sci.* **1053**, 289–300 (2005).
- 32. C. R. Gerfen, R. Paletzki, N. Heintz, GENSAT BAC cre-recombinase driver lines to study the functional organization of cerebral cortical and basal ganglia circuits. *Neuron* **80**, 1368–1383 (2013).
- C. R. Yang, J. K. Seamans, N. Gorelova, Electrophysiological and morphological properties of layers V-VI principal pyramidal cells in rat prefrontal cortex in vitro. *J. Neurosci.* 16, 1904–1921 (1996).
- 34. B. L. Roth, DREADDs for Neuroscientists. Neuron 89, 683–694 (2016).
- 35. M. M. S. Murray, M. J. Anesthesiology, Clinical Anesthesiology. (2006).
- H. J. Koester, B. Sakmann, Calcium dynamics in single spines during coincident pre- and postsynaptic activity depend on relative timing of back-propagating action potentials and subthreshold excitatory postsynaptic potentials. *Proc. Natl. Acad. Sci. U. S. A.* 95, 9596– 9601 (1998).
- 37. T. Nevian, B. Sakmann, Spine Ca2+ signaling in spike-timing-dependent plasticity. J. *Neurosci.* **26**, 11001–11013 (2006).
- P. Nagele, L. B. Metz, C. M. Crowder, Nitrous oxide (N(2)O) requires the N-methyl-D-aspartate receptor for its action in Caenorhabditis elegans. *Proc. Natl. Acad. Sci. U. S. A.* 101, 8791–8796 (2004).

- 39. J. Cichon, A. Z. Wasilczuk, L. L. Looger, D. Contreras, M. B. Kelz, A. Proekt, Ketamine triggers a switch in excitatory neuronal activity across neocortex. *Nat. Neurosci.* **26**, 39–52 (2023).
- 40. J. Cichon, T. J. J. Blanck, W.-B. Gan, G. Yang, Activation of cortical somatostatin interneurons prevents the development of neuropathic pain. *Nat. Neurosci.* **20**, 1122–1132 (2017).
- 41. J. Cichon, W.-B. Gan, Branch-specific dendritic Ca2+ spikes cause persistent synaptic plasticity. *Nature* **520**, 180–185 (2015).
- 42. S. Mennerick, V. Jevtovic-Todorovic, S. M. Todorovic, W. Shen, J. W. Olney, C. F. Zorumski, Effect of nitrous oxide on excitatory and inhibitory synaptic transmission in hippocampal cultures. *J. Neurosci.* **18**, 9716–9726 (1998).
- J. Dimidschstein, Q. Chen, R. Tremblay, S. L. Rogers, G.-A. Saldi, L. Guo, Q. Xu, R. Liu, C. Lu, J. Chu, J. S. Grimley, A.-R. Krostag, A. Kaykas, M. C. Avery, M. S. Rashid, M. Baek, A. L. Jacob, G. B. Smith, D. E. Wilson, G. Kosche, I. Kruglikov, T. Rusielewicz, V. C. Kotak, T. M. Mowery, S. A. Anderson, E. M. Callaway, J. S. Dasen, D. Fitzpatrick, V. Fossati, M. A. Long, S. Noggle, J. H. Reynolds, D. H. Sanes, B. Rudy, G. Feng, G. Fishell, A viral strategy for targeting and manipulating interneurons across vertebrate species. *Nat. Neurosci.* 19, 1743–1749 (2016).
- 44. K. Kullander, L. Topolnik, Cortical disinhibitory circuits: cell types, connectivity and function. *Trends Neurosci.* 44, 643–657 (2021).
- Z. Yao, C. T. J. van Velthoven, M. Kunst, M. Zhang, D. McMillen, C. Lee, W. Jung, J. Goldy, A. Abdelhak, P. Baker, E. Barkan, D. Bertagnolli, J. Campos, D. Carey, T. Casper, A. B. Chakka, R. Chakrabarty, S. Chavan, M. Chen, M. Clark, J. Close, K. Crichton, S. Daniel, T. Dolbeare, L. Ellingwood, J. Gee, A. Glandon, J. Gloe, J. Gould, J. Gray, N. Guilford, J. Guzman, D. Hirschstein, W. Ho, K. Jin, M. Kroll, K. Lathia, A. Leon, B. Long, Z. Maltzer, N. Martin, R. McCue, E. Meyerdierks, T. N. Nguyen, T. Pham, C. Rimorin, A. Ruiz, N. Shapovalova, C. Slaughterbeck, J. Sulc, M. Tieu, A. Torkelson, H. Tung, N. V. Cuevas, K. Wadhwani, K. Ward, B. Levi, C. Farrell, C. L. Thompson, S. Mufti, C. M. Pagan, L. Kruse, N. Dee, S. M. Sunkin, L. Esposito, M. J. Hawrylycz, J. Waters, L. Ng, K. A. Smith, B. Tasic, X. Zhuang, H. Zeng, A high-resolution transcriptomic and spatial atlas of cell types in the whole mouse brain, *bioRxiv* (2023). https://doi.org/10.1101/2023.03.06.531121.
- C. A. Sailer, W. A. Kaufmann, J. Marksteiner, H.-G. Knaus, Comparative immunohistochemical distribution of three small-conductance Ca2+-activated potassium channel subunits, SK1, SK2, and SK3 in mouse brain. *Mol. Cell. Neurosci.* 26, 458–469 (2004).
- 47. J. P. Adelman, J. Maylie, P. Sah, Small-conductance Ca2+-activated K+ channels: form and function. *Annu. Rev. Physiol.* **74**, 245–269 (2012).
- 48. J. Sun, Y. Liu, M. Baudry, X. Bi, SK2 channel regulation of neuronal excitability, synaptic

transmission, and brain rhythmic activity in health and diseases. *Biochim. Biophys. Acta Mol. Cell Res.* **1867**, 118834 (2020).

- 49. M. G. Nashed, S. Waye, S. M. N. Hasan, D. Nguyen, M. Wiseman, J. Zhang, H. Lau, O. C. Dinesh, R. Raymond, I. R. Greig, F. R. Bambico, J. N. Nobrega, Antidepressant activity of pharmacological and genetic deactivation of the small-conductance calcium-activated potassium channel subtype-3. *Psychopharmacology* **239**, 253–266 (2022).
- 50. J. Budni, A. E. Freitas, R. W. Binfaré, A. L. S. Rodrigues, Role of potassium channels in the antidepressant-like effect of folic acid in the forced swimming test in mice. *Pharmacol. Biochem. Behav.* **101**, 148–154 (2012).
- 51. R. Andrade, R. C. Foehring, A. V. Tzingounis, The calcium-activated slow AHP: cutting through the Gordian knot. *Front. Cell. Neurosci.* **6**, 47 (2012).
- 52. D. Guan, W. E. Armstrong, R. C. Foehring, Electrophysiological properties of genetically identified subtypes of layer 5 neocortical pyramidal neurons: Ca<sup>2+</sup> dependence and differential modulation by norepinephrine. *J. Neurophysiol.* **113**, 2014–2032 (2015).
- 53. E. Darve, D. Rodríguez-Gómez, A. Pohorille, Adaptive biasing force method for scalar and vector free energy calculations. *J. Chem. Phys.* **128**, 144120 (2008).
- 54. Y. Izumi, F.-F. Hsu, C. R. Conway, P. Nagele, S. J. Mennerick, C. F. Zorumski, Nitrous oxide, a rapid antidepressant, has ketamine-like effects on excitatory transmission in the adult hippocampus. *Biol. Psychiatry* **92**, 964–972 (2022).
- 55. P. Zanos, K. A. Brown, P. Georgiou, P. Yuan, C. A. Zarate Jr, S. M. Thompson, T. D. Gould, NMDA receptor activation-dependent antidepressant-relevant behavioral and synaptic actions of ketamine. *J. Neurosci.* **43**, 1038–1050 (2023).
- 56. A. J. Widman, L. L. McMahon, Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy. *Proc. Natl. Acad. Sci. U. S. A.* **115**, E3007–E3016 (2018).
- 57. F. Ali, D. M. Gerhard, K. Sweasy, S. Pothula, C. Pittenger, R. S. Duman, A. C. Kwan, Ketamine disinhibits dendrites and enhances calcium signals in prefrontal dendritic spines. *Nat. Commun.* **11**, 72 (2020).
- 58. M. V. Fogaça, R. S. Duman, Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions. *Front. Cell. Neurosci.* **13**, 87 (2019).

#### Acknowledgements

We thank all members of the Cichon lab including Marie Fina for critical support in animal breeding and genotyping. We also appreciate Dr. Alex Proekt for his assistance in analyzing the expression of different RNAs of interest amongst various cortical cell types.

Work supported by National Institutes of Health R35GM151160-01 and BBRF Young Investigator award to J.C., K08GM139031 to T.T.J., R01GM088156, R01 GM151556 to M.B.K and and MH122379 to C.F.Z and S.J.M.

#### **Author contributions**

J.C., M.B.K., P.N. initiated the project. J.C. performed the experiments and analyzed the behavior and imaging data. X. L, S.M., C.Z. performed in vitro L5 recordings of mAHPs. T.T.J. performed molecular dynamics simulations on SK2. A.W. performed and analyzed the EEG and RNA expression data set from Allen Brain. J.C. wrote the paper with input from all authors.

#### **Competing Interests**

No competing interests.

**Supplementary Materials** Materials and Methods Figs. S1 to S16 References Movie S1 to S2



Fig. 1. N<sub>2</sub>O induces rapid and specific activation of L5 pyramidal neurons to drive antidepressant-like response.

A, Left, chronic stress was induced with either corticosterone in tap water (CORT) or exposure to screened aggressive male CD-1 mouse (chronic aggressor interactions or CAI). CORT, CAI, and control (exposed to daily handling) mice were subjected to two-photon calcium imaging in the Cg1 (imaging location denoted by green highlighted region with dashed line to cell types) before, during, and after nitrous oxide (N<sub>2</sub>O) exposure. N<sub>2</sub>O was blended, delivered, and monitored under the microscope at 50% for 1 hr. Right, CaMK2-expressing excitatory neurons located in layer 2/3 (L2/3) and layer 5 (L5) in CORT mice. Top (room air) and bottom (N<sub>2</sub>O) images show 5 cells from each layer with their fluorescent transients from a 2 min time-series movie collapsed into a single image. Scale bar, 20  $\mu$ m.

**B-D**, Chronic stress (CORT, N<sub>2</sub>O n = 16, O<sub>2</sub> n = 12; CAI, N<sub>2</sub>O n = 11, O<sub>2</sub> n = 10) increased the time spent immobile in tail suspension test (TST) (**B**, avg. immobility time was  $153 \pm 7$  seconds in CORT and  $149 \pm 8$  seconds in CAI vs.  $86 \pm 7$  seconds in controls; Kruskal-Wallis (33): P = 5.6x 10<sup>-8</sup> followed by Dunn's multiple comparisons, control vs. CORT:  $P = 4.1 \times 10^{-7}$ , control vs. CAI:  $P = 6.8 \times 10^{-6}$ , decreased exploration of open arms in an elevated plus maze (EPM) (C, avg. open arm time was  $113 \pm 11$  seconds in CORT and  $115 \pm 16$  seconds in CAI vs.  $238 \pm 19$ seconds in control mice; Kruskal-Wallis (31):  $P = 1.6 \times 10^{-7}$  followed by Dunn's multiple comparisons, control vs. CORT:  $P = 1.3 \times 10^{-6}$ , control vs. CAI:  $P = 1.0 \times 10^{-5}$ ), and reduced sucrose preference index (SPI) (**D**, avg. SPI was  $0.06 \pm 0.1$  in CORT and  $0.1 \pm 0.1$  in CAI vs.  $0.5 \pm 0.1$  in control mice; Kruskal-Wallis (22):  $P = 1.6 \times 10^{-7}$  followed by Dunn's multiple comparisons, control vs. CORT:  $P = 2.5 \times 10^{-5}$ , control vs. CAI:  $P = 8.7 \times 10^{-4}$ ), as compared to control mice (N<sub>2</sub>O n = 14, O<sub>2</sub> n = 14). N<sub>2</sub>O, but not O<sub>2</sub>, therapy rapidly reversed the effects of chronic stress (2-way ANOVA time x treatment: TST CORT,  $F_{(2, 78)} = 8.1$ ,  $P = 8.6 \times 10^{-4}$ , TST CAI,  $F_{(2, 38)} = 7.4$ , P = 0.002; EPM CORT,  $F_{(2, 78)} = 6.5$ , P = 0.002, EPM CAI,  $F_{(2, 38)} = 3.0$ , P = 0.06; SPI CORT,  $F_{(2, 52)} = 4.0$ , P = 0.02, SPI CAI,  $F_{(2, 57)} = 7.6$ , P = 0.001). Post treatment comparisons (N<sub>2</sub>O, blue; O<sub>2</sub>, green) are shown in panel.

E, Representative GCaMP6 traces of the spontaneous activity of individual neurons from L2/3 and L5, shown in A, under wakefulness followed by oxygen (left, green) or N<sub>2</sub>O (right, blue) in control and chronically stressed mice. N<sub>2</sub>O induced the rapid recruitment of L5 neurons as compared to L2/3 across all conditions.

**F**, Individual neuronal responses (circles) under room air (yellow) and N<sub>2</sub>O (blue) from all recording regions across Cg1 from control (left) and chronically stressed (middle/CORT and right/CAI) mice. Oxygen plot in **Fig. S4A**.

G, L2/3 and L5 population response (colored squares) under room air and N<sub>2</sub>O across control (L2/3: n = 121; L5: n = 102 from 8 mice) and CORT (L2/3: n = 96; L5: n = 122 from 9 mice)/CAI mice (L2/3: n = 61; L5: n = 98 from 4 mice). N<sub>2</sub>O drove the rapid L5 activation across stressed and control mice (Kruskal-Wallis (390):  $P = 5.3 \times 10^{-77}$  followed by Dunn's multiple comparisons, control:  $P = 4.8 \times 10^{-12}$ , CORT:  $P = 4.8 \times 10^{-28}$ , CAI:  $P = 3.9 \times 10^{-33}$ ) as opposed to L2/3 (Kruskal-Wallis: control/CORT/CAI: P > 0.99). L5 neurons from chronically stressed mice displayed a hypoactivity state relative to control mice (from prior Dunn's test: CORT, P = 0.006; CAI, P = 0.04). L2/3 activity was also reduced but not significant (CORT, P = 0.80; CAI, P = 0.11).

**H**, L5 calcium responses under room air and N<sub>2</sub>O across different genetically defined L5 neuronal subtypes (Kruskal-Wallis (404):  $P = 4.4 \times 10^{-85}$  followed by Dunn's multiple comparisons, Rbp4 (n = 89 from 3 mice):  $P = 1.8 \times 10^{-17}$ , Tlx3 (n = 196 from 4 mice):  $P = 2.9 \times 10^{-36}$ ; Colgalt2 (n = 149 from 4 mice): P > 0.99).

I, CaMK2-expressing L5 neuronal responses at different N<sub>2</sub>O concentrations (0, 25, 50, 75% mixed with O<sub>2</sub>). L5 activating effect observed at 25% with peak effect at 50% (Two-way ANOVA with Bonferroni's comparisons: 25%, P = 0.03; 50%,  $P = 4.2 \times 10^{-7}$ ; 75%, P = 0.08). J, Left, coronal sections of Cg1 from Rbp4-Cre mouse expressing either Cre-dependent chemogenetic variant (tagged with mCherry) hM<sub>3</sub>G<sub>q</sub> (green) or hM<sub>4</sub>G<sub>i</sub> (red; Scale bar 100 µm). Right, representative GCaMP6 traces (bottom) and two-photon images (top) of individual L5 neurons recorded during room air and following CNO injection (orange shared area). Scale bar, 20 µm.

**K**, CNO-induced Rbp4-L5 neuronal inactivation with hM<sub>4</sub>G<sub>i</sub> bilaterally in Cg1 (n = 22) blocked N<sub>2</sub>O's effect on TST whereas CNO-induced Rbp4-L5 activation with hM<sub>3</sub>G<sub>q</sub> (n = 14) masked N<sub>2</sub>O's effect (two-way ANOVA time x treatment F<sub>(4, 166)</sub> = 19.8,  $P = 1.9 \times 10^{-12}$  post hoc Sidak's comparisons shown in panel following N<sub>2</sub>O exposure. Representative images and traces carried out on at least three animals per group. Error bars show s.e.m.



**Fig. 2.** Persistent L5 activity following N<sub>2</sub>O elimination contributes to L2/3 recruitment. A-B, The same individual L5 (A) and L2/3 (B) neuronal responses under room air (left), O<sub>2</sub>, or N<sub>2</sub>O (middle), 1 hr after O<sub>2</sub> or N<sub>2</sub>O (right) in control, CORT-treated and CAI mice . Note the persistent activity of L5 neurons and recruitment of L2/3 neurons following N<sub>2</sub>O . C, Summary of individual (circles) and population (colored squares connected by black line) neuronal responses of both L5 and L2/3 neurons across wakefulness, N<sub>2</sub>O exposure, and following N<sub>2</sub>O exhalation in control (L2/3: n = 52; L5: n = 88 from 3 mice) and CORT (L2/3: n = 43; L5: n = 163 from 5 mice)/CAI (L2/3: n = 61; L5: n = 97 from 4 mice) mice. Cohort different from Fig. 1). Persistent activation of L5 was observed at 1 hr following N<sub>2</sub>O exposure in all groups (Kruskal-Wallis (559):  $P = 5.5 \times 10^{-108}$  followed by Dunn's multiple comparisons, control, P = 0.06; CORT,  $P = 4.4 \times 10^{-12}$ ; CAI,  $P = 1.4 \times 10^{-18}$ ) while significant L2/3 activation was observed in only CORT-treated and CAI groups at 1 hr following N<sub>2</sub>O exposure (prior Dunn's test: control, P > 0.99; CORT, P = 0.03; CAI,  $P = 1.1 \times 10^{-6}$ ).

**D**, Schematic illustrating that hypoactive L5 neurons (black cells) become rapidly activated by  $N_2O$  treatment (green cells). Following  $N_2O$  exhalation, persistent L5 activity, from local or distant regions (green activated cells), may recruit L2/3 (superficial green cells receiving projections).

**E**, Experimental design to test whether 1) direct local chemogenetic L5 activation results in recruitment of local L2/3 neurons (left), 2) Post-N<sub>2</sub>O recruitment of L2/3 is dependent upon persistent local and distant L5 activity.

**F**, Individual L2/3 neurons responses corresponding to **E**. Top, L2/3 responses before and after CNO-induced activation of L5 neurons expressing  $hM_3G_q$  (n = 161 from 5 mice). Middle and

bottom traces, L2/3 responses following either ipsilateral (n = 42 from 2 mice) or bilateral (n = 77 from 3 mice) hM<sub>4</sub>G<sub>i</sub>-mediated L5 inhibition respectively.

**G**, Summary of individual L2/3 responses from **E**. CNO-induced activation of L5-hM<sub>3</sub>G<sub>q</sub> drove superficial L2/3 activity (Wilcoxon matched-pairs signed rank test:  $P = 2.2 \times 10^{-30}$ ). Either ipsilateral (Kruskal-Wallis (26.8):  $P = 1.5 \times 10^{-6}$  followed by Dunn's multiple comparisons, post-N<sub>2</sub>O:  $P = 1.2 \times 10^{-6}$ ; post-CNO: P = 0.31) or bilateral (Kruskal-Wallis (26.9):  $P = 1.4 \times 10^{-6}$  followed by Dunn's multiple comparisons, post-N<sub>2</sub>O: P = 0.002; post-CNO: P = 0.27) CNO-induced L5-hM<sub>4</sub>G<sub>i</sub> inhibition reduced post-N<sub>2</sub>O-induced L2/3 activity to baseline wakefulness. Error bars show s.e.m.



Fig. 3. Reduced NMDA-receptor activity does not impair N<sub>2</sub>O-induced L5 activation *in vivo*.

A, Top, timeline of L5 imaging (teal box) before, following local (L-) drug application (red cloud), and during N<sub>2</sub>O exposure (blue shaded region). Middle, cartoon and coronal section of Cg1 region after pressure application of MK801 mixed with Rhodamine 6G. Scale bar, 500  $\mu$ m. Bottom, Representative two-photon images of peak GCaMP6 signal from Cg1 L5 neurons under room air conditions, L-MK801, N<sub>2</sub>O.

C, Representative GCaMP6 traces of L5 neurons under room air conditions, L-MK801 (top – high concentration/100  $\mu$ M; n = 103 from 3 mice; middle – low concentration/10  $\mu$ M; n = 202 from 4 mice), or L-MK801 + CNQX (lower traces; each drug at 100  $\mu$ M mixed; n = 96 from 3 mice) followed by N<sub>2</sub>O exposure.

C, Representative GCaMP6 traces of L5 neurons from mice infected with siRNA specific to GRIN1 (top; n = 165 from 4 mice) and scramble-siRNA (bottom; n = 116 from 4 mice) under room air, N<sub>2</sub>O, following N<sub>2</sub>O.

**D**, Summary of individual L5 responses (from **B-C**) normalized to its baseline captured under room air conditions (Kruskal-Wallis (513):  $P = 4.3 \times 10^{-103}$  followed by Dunn's multiple comparisons, L-MK801 100  $\mu$ M,  $P = 1.5 \times 10^{-11}$ ; L-MK801 10  $\mu$ M,  $P = 1.8 \times 10^{-22}$ ; L-APV,  $P = 1.3 \times 10^{-6}$ ; L-MK801 + CNQX,  $P = 2.0 \times 10^{-23}$ ; GRIN1-siRNA,  $P = 3.8 \times 10^{-18}$ ; Scramble siRNA,  $P = 5.0 \times 10^{-15}$ ).

E, L5 imaging of CORT mice exposed different drug sequences. Top, room air, L-ketamine (100  $\mu$ M; n = 243 from 4 mice), followed by N<sub>2</sub>O. Middle 2 traces, room air, N<sub>2</sub>O exposure, followed by systemic ketamine (10 mg/kg i.p. injection; n = 88 neurons from 3 mice) and its reverse order (ketamine then N<sub>2</sub>O; n = 140 neurons from 4 mice). Bottom, room air  $\rightarrow$  N<sub>2</sub>O  $\rightarrow$  systemic ketamine  $\rightarrow$  N<sub>2</sub>O re-exposure (n = 104 neurons from 3 mice).

**F**, L5 responses from **E** (Kruskal-Wallis (135):  $P = 2.5 \ge 10^{-25}$  followed by Dunn's multiple comparisons, L-ketamine  $\rightarrow N_2O$ ,  $P = 4.6 \ge 10^{-4}$ ;  $N_2O \rightarrow ketamine$ ,  $P = 5.1 \ge 10^{-13}$ ; ketamine  $\rightarrow N_2O$ , P > 0.99;  $N_2O \rightarrow ketamine \rightarrow N_2O$ , P = 0.005;  $N_2O \rightarrow ketamine \rightarrow N_2O$ , P > 0.99). **G**, N<sub>2</sub>O-induced activity was negatively correlated with ketamine-induced activity in L5 neurons (Pearson correlation: N<sub>2</sub>O  $\rightarrow$  ketamine, r = -0.83,  $P = 1.8 \ge 10^{-49}$ ; ketamine  $\rightarrow N_2O$ , r = -0.24, P = 0.004). Error bars show s.e.m.





A, Representative two-photon GCaMP6 image of L5 apical dendritic segment (DS; teal box) containing 4 spines (S1, S2, S3, S4) in 2-D imaging plane. Spontaneous spine activity (middle image showing peak signal of single spine activation) is occasionally observed in min recordings under room air conditions. N<sub>2</sub>O fails to recruit spine activity (n = 66 spines from 9 mice, Wilcoxon matched-pairs signed rank test: P = 0.22). Scale bar, 5 µm.

**B**, Left, two-photon z-stack of an individual L5 neuron coexpressing GCaMP6 and tdTomato. Middle, multiple 2-D imaging planes across L5 neuron from apical tuft dendrites to soma corresponding to the teal boxes located on z-stack. ROI labeled D for apical dendrite, P for parent dendrite, T for trunk. Right, GCaMP6 traces for ROIs under room air, N<sub>2</sub>O inhalation, and following N<sub>2</sub>O exhalation. N<sub>2</sub>O fails to recruit superficial dendrites during treatment. Dendritic activity is found deep, in close proximity to soma. Scale bar, 20 μm.

C, Summary of calcium responses from across different L5 dendritic compartments (dendritic segments: n = 170 from 21 mice, Wilcoxon matched-pairs signed rank test: P = 0.19; deep dendrites/trunks: n = 34 from 14 mice, Wilcoxon matched-pairs signed rank test: P = 0.03) and soma (n = 47 from 19 mice, Wilcoxon matched-pairs signed rank test:  $P = 2.2 \times 10^{-5}$ ). D, Left, Z-stack of L5 neuron coexpressing GCaMP6 and tdTomato subject to dendritomies by 2-photon laser pulses. Right, GCaMP6 traces of dendritic ROIs and soma under wakefulness, N<sub>2</sub>O, and following dendritomies. L5 soma and dendrites were activated by N<sub>2</sub>O as compared to wakefulness. GCaMP images of two parents dendrites corresponding to teal box in Z-stack (ROI 1 and 2 at 136 µm) are targeted and sequentially cut using laser pulses resulting in a baseline fluorescence bump coupled with the elimination of transients. L5 activity persists following dendritomies despite loss of dendritic activity. Scale bar, 20 µm.

E, Top, Summary of individual L5 calcium activity following N<sub>2</sub>O exposure and apical dendritomies (n = 5 L5 neurons from 5 mice). Bottom, L5 neurons under same conditions exposed to focal two-photon laser pulses directed at neuropil (control; n = 7 L5 neurons from 7 mice). L5 responses following neuropil pulses were not significantly different than those directed at dendrites (Mann Whitney rank sum (13): P = 0.53). Error bars show s.e.m.



## Fig. 5. N<sub>2</sub>O-induced L5 activity and antidepressant-like effect requires GABAergic disinhibition.

**A**, Left, Schematic of GABAergic neurons (circles) scattered amongst pyramidal neurons (triangles). While all interneurons can be labeled with GCaMP6 using the *mDlx* enhancer (outer magenta), subtypes including PV (purple), SST (orange), and VIP (green) can be specifically labeled using Cre transgenic lines depicted on right. Dendritic targeting SST cells and somatic targeting PV are inhibited (circled negative sign) by VIP interneurons.

**B**, Two-photon images of peak GCaMP6 signals from interneuron subtypes under room air and  $N_2O$  (50%). Scale bar, 20  $\mu$ m. Traces in **fig. S13**.

C, Summary of genetically defined interneuron calcium responses under room air and N<sub>2</sub>O. N<sub>2</sub>O induces a suppression of PV and SST spontaneous activity but activates VIP activity (Wilcoxon matched-pairs signed rank: mDlx, n = 133 cells from 5 mice,  $P = 2.9 \times 10^{-13}$ ; PV, n = 145 cells from 7 mice,  $P = 2.9 \times 10^{-22}$ ; SST, n = 63 cells from 4 mice,  $P = 1.5 \times 10^{-13}$ ; VIP, n = 197 cells from 10 mice, P = 0.0003).

D, Interneuron subtypes coexpressing GCaMP6 and DREADD-hM<sub>3</sub>G<sub>q</sub> recorded under wakefulness, post-CNO injection, and N<sub>2</sub>O (50%). CNO-hM<sub>3</sub>G<sub>q</sub> induced activation of interneuron subtypes blocked N<sub>2</sub>O induced suppression of PV (n = 84 cells from 3 mice; Kruskal-Wallis (347):  $P = 3.0 \times 10^{-76}$  followed by Dunn's multiple comparisons, P > 0.99) and SST activity (n = 103 cells from 3 mice; Kruskal-Wallis (68):  $P = 2.0 \times 10^{-15}$  followed by Dunn's multiple comparisons, P > 0.99). VIP cells displayed a similar trend (n = 97 cells from 4 mice; Kruskal-Wallis (93):  $P = 6.8 \times 10^{-21}$  followed by Dunn's multiple comparisons, P = 0.30). E, Left, representative GCaMP6 traces of individual L5 responses and summary of all cells (right) under room air, post-CNO injection, and N<sub>2</sub>O. CNO-induced activation of PV (n = 241cells from 7 mice; Kruskal-Wallis (348):  $P = 3.0 \times 10^{-76}$  followed by Dunn's multiple comparisons, P > 0.99) or SST (n = 110 cells from 3 mice; Kruskal-Wallis (112):  $P = 3.3 \times 10^{-25}$ followed by Dunn's multiple comparisons, P = 0.001) blocked N<sub>2</sub>O-induced L5 activation whereas VIP promoted N<sub>2</sub>O-induced L5 activity (n = 139 cells from 3 mice, Kruskal-Wallis (169):  $P = 1.8 \times 10^{-37}$  followed by Dunn's multiple comparisons,  $P = 1.4 \times 10^{-14}$ ). **F**, TST immobility time under the same conditions. PV (n = 13, Kruskal-Wallis (9): P = 0.01followed by Dunn's multiple comparisons, P > 0.99) and SST (n = 17, Kruskal-Wallis (27): P =1.4 x 10<sup>-6</sup> followed by Dunn's multiple comparisons, P > 0.99) activation by hM<sub>3</sub>G<sub>q</sub> blocked N<sub>2</sub>O-induced decrease in immobility time in CORT mice. VIP activation prior to N<sub>2</sub>O produced a significant decrease in immobility time (n = 14, Kruskal-Wallis (10): P = 0.006 followed by Dunn's multiple comparisons, P = 0.03). Error bars show s.e.m.



#### Fig. 6. N<sub>2</sub>O inhibits medium afterhyperpolarization potentials in L5 neurons.

A, Mouse Cg1 coronal section immunostained for SK2 channel. SK2-positive cells are more prominent in L5 as opposed to L2/3. Scale bar,  $20 \,\mu$ m.

**B**, Representative voltage traces of action potentials and medium afterhyperpolarization potentials (mAHPs) elicited by a 400 pA current injection under baseline conditions (black) and with 30% N<sub>2</sub>O (blue). Inset shows magnified mAHP as indicated by the teal box.

C, Summary data of mAHP amplitude across different current injection intensities (200-400 pA) under baseline (black) and 30% N<sub>2</sub>O (blue) conditions (n = 9 neurons from 4 mice). Two-way, repeated-measures ANOVA shows a main effect of N<sub>2</sub>O on the amplitude of mAHP (F<sub>(1,8)</sub> = 26.43, P < 0.001). Sidak's post-hoc test results for individual current injections are shown. D, Representative control voltage traces under baseline conditions (black) and with 30% nitrogen (N<sub>2</sub>) (magenta).

**E**, Summary data of mAHP amplitudes across different current injection intensities under baseline (black) and 30% N<sub>2</sub> (blue) conditions (n = 7 neurons from 3 mice). Two-way ANOVA shows no effect of N<sub>2</sub> on mAHP amplitude (F<sub>(1,6)</sub> = 0.279, P = 0.616), ns: P = 0.616. Data are presented as mean ± SEM.



## Fig. 7. Pharmacological inhibition of SK2 channels drives rapid L5 and VIP activation and antidepressant-like response

**A**, Representative GCaMP6 traces of individual L5 neurons under room air followed by local (L-) application of apamin to Cg1 (L-APA, 100 uM, 1 uL). Specific cell type noted left of traces. L5 and VIP neurons are spontaneously activated by L-APA whereas L2/3 pyramidal cells, PV, and SST cells fail to be recruited by L-APA.

**B**, Summary of drug-induced inhibition of SK2 responses across different neuronal cell types (Kruskal-Wallis (455):  $P = 2.0 \times 10^{-92}$  followed by Dunn's multiple comparisons, L5 APA, n = 90 from 3 mice,  $P = 2.2 \times 10^{-17}$ ; L5 NS8593, n = 114 from 3 mice,  $P = 4.5 \times 10^{-11}$ ; L5 APA/APV, n = 110 from 3 mice,  $P = 1.8 \times 10^{-23}$ ; CORT-treated L5 APA, n = 145 from 4 mice,  $P = 4.2 \times 10^{-20}$ ; VIP APA, n = 114 from 3 mice,  $P = 3.5 \times 10^{-12}$ ; L2/3 APA, n = 41 from 2 mice, P = 0.99; L2/3 NS8593, n = 93 from 3 mice, P = 0.11; PV APA, n = 138 from 3 mice, P = 0.16; SST APA, n = 126 from 5 mice, P > 0.99).

C, TST immobility time of CORT-treated mice injected with APA (0.1 mg/kg) or saline. APAinjected mice (n = 17) were significantly different from saline (n = 17) at 1 hr post injection and 24 hr later (Mann Whitney rank sum: 1 hr, P = 0.0002; 24 hr, P = 0.001).

**D**, Left, individual GCaMP6 traces of L2/3, PV, SST neurons overexpressing SK2 showing effect of  $N_2O$  (blue shaded region). Right, effect of  $N_2O$  or APA (magenta shaded region) on L5 and VIP neurons expressing SK2-shRNA.

E, Summary of SK2 overexpression and knockdown effects across different neuronal cell-types (Kruskal-Wallis (395):  $P = 2.3 \times 10^{-82}$  followed by Dunn's multiple comparisons, SK2 overexpression in L2/3, n = 66 from 2 mice,  $P = 8.6 \times 10^{-14}$ ; PV, n = 228 from 5 mice,  $P = 7.8 \times 10^{-13}$ ; SST, n = 86 from 5 mice,  $P = 1.2 \times 10^{-12}$  versus SK2 knockdown in L5, n = 151 from 4 mice, P > 0.99; L5 APA, n = 81 from 2 mice,  $P = 1.6 \times 10^{-5}$ ; VIP, n = 118 from 4 mice,  $P = 3.8 \times 10^{-8}$ ).

**F**, CORT-treated mice with bilateral expression of SK2-shRNA (n = 12) exposed to N<sub>2</sub>O fail to decrease their immobility time in response to N<sub>2</sub>O exposure as compared to O<sub>2</sub> (n = 6; Mann Whitney rank sum: P = 0.25).



#### Fig. 8. N<sub>2</sub>O could act as a channel pore blocker to induce SK2 channel inhibition

**A**, N<sub>2</sub>O embedded in selectivity filter of SK2 homology model, representative snapshot from equilibrium MD simulation.

**B**, Oblique view from extracellular side.

C, PMF curve generated by ABF simulations. Free energy (y-axis) is plotted as a function of relative  $N_2O$  z-distance (x-axis). Dotted vertical lines represent displacement of  $N_2O$  along pore axis 2 Å in either direction, approaching the top and bottom of the filter. Shaded areas represent standard error with respect to the mean (standard deviation divided by square root of number of replicates).

**D**, Working model of N<sub>2</sub>O-induced modulation of L5 neurons via SK2 inhibition to drive Cg1 circuit activation to rescue chronic stress-associated hypoactivity state. Chronic stress induces L5 synaptic loss (open circles) and hypoactivity (thin connections) compared to non-stress condition. N<sub>2</sub>O-induced SK2 inhibition in cells with high SK2 expression (L5 and VIP cells) drives their rapid spontaneous activation (circular red arrow), which can arise in the presence of NMDA-receptor blockade. L5 neurons recruited during N<sub>2</sub>O exposure can engage other cortical circuit elements, *i.e.* superficial L2/3 neurons upon N<sub>2</sub>O elimination. Following N<sub>2</sub>O treatment, persistent spontaneous activity in both L5 and L2/3 is likely to lead to durable changes circuit function.

### **Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- NCSupplementalDatafinal.pdf
- SDattack.mp4
- Nitrousmovie.mp4